6H-1,2,3-Triazolo[4,5,1-ij]cinnoline | 209-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 6H-1,2,3-Triazolo[4,5,1-ij]cinnoline
• 英文别名: 1,2,3,11-tetrazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12),10-pentaene
• CAS: 209-34-7
• 化学式: C₈H₆N₄
• 分子量: 158.16
• InChiKey: GGJCVRTVDVEOJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO<br/>[FR] ANTAGONISTES DU RECEPTEUR DE CRF ET PROCEDES CORRESPONDANTS
  申请人：SB PHARMCO INC

  公开号：WO2005063749A1

  公开（公告）日：2005-07-14

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders in mammals, including the treatment of disorders, such as stroke, manifesting hypersecretion of CRF. The CRF receptor antagonists of this invention have the following structure (a) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了具有在哺乳动物中治疗多种疾病的效用的CRF受体拮抗剂，包括用于治疗出现CRF高分泌的疾病，如中风的治疗。本发明的CRF受体拮抗剂具有以下结构（a），包括立体异构体、前药和其药用盐，其中R1、R2、R5、Ar和Het的定义如本文所述。还披露了含有CRF受体拮抗剂的组合物，其中包括与药用载体结合，以及其使用方法。
• Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
  申请人：——

  公开号：US20040198726A1

  公开（公告）日：2004-10-07

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure of formula (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, R1, R2, R4, R5, R6, A, X, and Y are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same. 1

  本发明公开了CRF受体拮抗剂，这些拮抗剂可用于治疗多种疾病，包括治疗温血动物CRF分泌过多的疾病，如中风。本发明的 CRF 受体拮抗剂具有如下式（I）结构：包括其立体异构体、原药和药学上可接受的盐，R1、R2、R4、R5、R6、A、X 和 Y 如本文所定义。还公开了含有 CRF 受体拮抗剂与药学上可接受的载体结合的组合物，以及使用这些组合物的方法。 1
• CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
  申请人：SB Pharmco Puerto Rico Inc.

  公开号：EP1697362A1

  公开（公告）日：2006-09-06
• Crf Receptor Antagonists and Methods Relating Thereto
  申请人：Williams John

  公开号：US20070293508A1

  公开（公告）日：2007-12-20

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders in mammals, including the treatment of disorders, such as stroke, manifesting hypersecretion of CRF. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 5 , Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
• US6013793A
  申请人：——

  公开号：US6013793A

  公开（公告）日：2000-01-11